Featured News
855NewsAromajoin Announces Six Finalists for Its First Ever Digital Scent-Inspired Hackathon, Hackaroma
Hackaroma is the world’s first scent-inspired hackathon. It has decided six finalists for the next development round. Those six projects include a...
- 820News
Integrated Investment Research Quarterly Earnings Report Jan-April 2020
Tokyo, Japan, May 30, 2020 –(PR.com)– Integrated Investment Research announced their start to the year earnings this week, with better than expected...
- 838Wire Stories
ViaBTC Group Announces Strategic Upgrade to Advance Innovation and Improve Customer Experience
HONG KONG–(BUSINESS WIRE)–ViaBTC Group, an innovative technology company specialized in blockchain and dedicated to providing users with comprehensive digital asset management services,...
- 871News
TIS Raises $20m as Demand Grows for Its Leading SaaS B2B Payment Platform
Investment from Aquiline and 83North will be used to continue rapid global expansion. Walldorf, Germany, May 29, 2020 –(PR.com)– TIS (Treasury Intelligence...
- 832News
Ares is Only Taiwan Commercial Service Vendor Certified by ISDA SIMM™
Taipei, Taiwan, May 30, 2020 –(PR.com)– Ares International Corp. was recently certified by International Swaps and Derivatives Association (ISDA) to offer commercial...
- 844Wire Stories
Crash Barrier Systems Market 2020-2024 | Implementation of Road Safety Programs to Boost Market Growth | Technavio
LONDON–(BUSINESS WIRE)–#CrashBarrierSystemsMarket–The crash barrier systems market is expected to grow by USD 1.29 billion during 2020-2024. The report also provides the market...
- 1.1KNews
Dr. Jacob Frydman Online Pet Care Offers Veterinary Services for Non-Critical Pet Care Issues
Most non-critical pet care issues can be addressed & diagnosed online. An experienced veterinarian from Dr. Jacob Frydman Pet Care can offer...
- 1.3KWire Stories
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
61.9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently...
- 1.2KWire Stories
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
TOKYO & BASKING RIDGE, N.J. & MUNICH–(BUSINESS WIRE)–Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)...
- 975Wire Stories
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
Validation of Type II Variation will allow Takeda to commence launches in Europe later this year The pre-filled syringe presentation is designed...
- 849Wire Stories
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
DAEJEON, South Korea–(BUSINESS WIRE)–#ALTB4—Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of ALT-P7, a...
